Physician profile
Joanna Johnson
NPI 1689638116
$2,340.37
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $653 · 2023: $813 · 2024: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $336.49 | 2021-2024 | |
| Biocryst US Sales Co., LLC | $264.89 | 2021-2024 | Orladeyo |
| Glaxosmithkline, LLC. | $245.52 | 2021-2024 | Nucala |
| Csl Behring | $214.76 | 2022-2024 | Haegarda, Hizentra |
| Astrazeneca Pharmaceuticals LP | $212.32 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.94 | 2021-2023 | Stiolto Respimat |
| Alexion Pharmaceuticals, INC. | $119.79 | 2023 | |
| Optinose US, INC. | $118.70 | 2023 | |
| Amgen INC. | $113.09 | 2021-2023 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $103.39 | 2023 | |
| Blueprint Medicines Corporation | $90.88 | 2023 | Ayvakit |
| Octapharma USA, INC. | $61.66 | 2022-2024 | Cutaquig |
| Novo Nordisk INC | $53.63 | 2023-2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $39.75 | 2024 | Takhzyro |
| Acclarent, INC | $38.26 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $35.96 | 2023 | Auvi-Q |
| Alk-Abello, INC | $30.29 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Incyte Corporation | $28.30 | 2021 | |
| Pfizer INC. | $20.50 | 2021 | |
| Genentech USA, INC. | $19.15 | 2023 | Xolair |
| Aimmune Therapeutics, INC. | $16.37 | 2021 | |
| Leo Pharma INC. | $15.94 | 2022 | |
| Aytu Biopharma, INC. | $14.87 | 2021 | |
| Covis Pharma Gmbh | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.